• Something wrong with this record ?

Differential glycosylation of envelope gp120 is associated with differential recognition of HIV-1 by virus-specific antibodies and cell infection

M. Raska, L. Czernekova, Z. Moldoveanu, K. Zachova, MC. Elliott, Z. Novak, S. Hall, M. Hoelscher, L. Maboko, R. Brown, PD. Smith, J. Mestecky, J. Novak,

. 2014 ; 11 (-) : 23.

Language English Country England, Great Britain

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc14074835

BACKGROUND: HIV-1 entry into host cells is mediated by interactions between the virus envelope glycoprotein (gp120/gp41) and host-cell receptors. N-glycans represent approximately 50% of the molecular mass of gp120 and serve as potential antigenic determinants and/or as a shield against immune recognition. We previously reported that N-glycosylation of recombinant gp120 varied, depending on the producer cells, and the glycosylation variability affected gp120 recognition by serum antibodies from persons infected with HIV-1 subtype B. However, the impact of gp120 differential glycosylation on recognition by broadly neutralizing monoclonal antibodies or by polyclonal antibodies of individuals infected with other HIV-1 subtypes is unknown. METHODS: Recombinant multimerizing gp120 antigens were expressed in different cells, HEK 293T, T-cell, rhabdomyosarcoma, hepatocellular carcinoma, and Chinese hamster ovary cell lines. Binding of broadly neutralizing monoclonal antibodies and polyclonal antibodies from sera of subtype A/C HIV-1-infected subjects with individual gp120 glycoforms was assessed by ELISA. In addition, immunodetection was performed using Western and dot blot assays. Recombinant gp120 glycoforms were tested for inhibition of infection of reporter cells by SF162 and YU.2 Env-pseudotyped R5 viruses. RESULTS: We demonstrated, using ELISA, that gp120 glycans sterically adjacent to the V3 loop only moderately contribute to differential recognition of a short apex motif GPGRA and GPGR by monoclonal antibodies F425 B4e8 and 447-52D, respectively. The binding of antibodies recognizing longer peptide motifs overlapping with GPGR epitope (268 D4, 257 D4, 19b) was significantly altered. Recognition of gp120 glycoforms by monoclonal antibodies specific for other than V3-loop epitopes was significantly affected by cell types used for gp120 expression. These epitopes included CD4-binding site (VRC03, VRC01, b12), discontinuous epitope involving V1/V2 loop with the associated glycans (PG9, PG16), and an epitope including V3-base-, N332 oligomannose-, and surrounding glycans-containing epitope (PGT 121). Moreover, the different gp120 glycoforms variably inhibited HIV-1 infection of reporter cells. CONCLUSION: Our data support the hypothesis that the glycosylation machinery of different cells shapes gp120 glycosylation and, consequently, impacts envelope recognition by specific antibodies as well as the interaction of HIV-1 gp120 with cellular receptors. These findings underscore the importance of selection of appropriately glycosylated HIV-1 envelope as a vaccine antigen.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc14074835
003      
CZ-PrNML
005      
20210121125414.0
007      
ta
008      
141006s2014 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/1742-6405-11-23 $2 doi
035    __
$a (PubMed)25120578
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Raska, Milan $u Department of Immunology, Palacky University in Olomouc, 77100 Olomouc, Czech Republic ; Department of Microbiology, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
245    10
$a Differential glycosylation of envelope gp120 is associated with differential recognition of HIV-1 by virus-specific antibodies and cell infection / $c M. Raska, L. Czernekova, Z. Moldoveanu, K. Zachova, MC. Elliott, Z. Novak, S. Hall, M. Hoelscher, L. Maboko, R. Brown, PD. Smith, J. Mestecky, J. Novak,
520    9_
$a BACKGROUND: HIV-1 entry into host cells is mediated by interactions between the virus envelope glycoprotein (gp120/gp41) and host-cell receptors. N-glycans represent approximately 50% of the molecular mass of gp120 and serve as potential antigenic determinants and/or as a shield against immune recognition. We previously reported that N-glycosylation of recombinant gp120 varied, depending on the producer cells, and the glycosylation variability affected gp120 recognition by serum antibodies from persons infected with HIV-1 subtype B. However, the impact of gp120 differential glycosylation on recognition by broadly neutralizing monoclonal antibodies or by polyclonal antibodies of individuals infected with other HIV-1 subtypes is unknown. METHODS: Recombinant multimerizing gp120 antigens were expressed in different cells, HEK 293T, T-cell, rhabdomyosarcoma, hepatocellular carcinoma, and Chinese hamster ovary cell lines. Binding of broadly neutralizing monoclonal antibodies and polyclonal antibodies from sera of subtype A/C HIV-1-infected subjects with individual gp120 glycoforms was assessed by ELISA. In addition, immunodetection was performed using Western and dot blot assays. Recombinant gp120 glycoforms were tested for inhibition of infection of reporter cells by SF162 and YU.2 Env-pseudotyped R5 viruses. RESULTS: We demonstrated, using ELISA, that gp120 glycans sterically adjacent to the V3 loop only moderately contribute to differential recognition of a short apex motif GPGRA and GPGR by monoclonal antibodies F425 B4e8 and 447-52D, respectively. The binding of antibodies recognizing longer peptide motifs overlapping with GPGR epitope (268 D4, 257 D4, 19b) was significantly altered. Recognition of gp120 glycoforms by monoclonal antibodies specific for other than V3-loop epitopes was significantly affected by cell types used for gp120 expression. These epitopes included CD4-binding site (VRC03, VRC01, b12), discontinuous epitope involving V1/V2 loop with the associated glycans (PG9, PG16), and an epitope including V3-base-, N332 oligomannose-, and surrounding glycans-containing epitope (PGT 121). Moreover, the different gp120 glycoforms variably inhibited HIV-1 infection of reporter cells. CONCLUSION: Our data support the hypothesis that the glycosylation machinery of different cells shapes gp120 glycosylation and, consequently, impacts envelope recognition by specific antibodies as well as the interaction of HIV-1 gp120 with cellular receptors. These findings underscore the importance of selection of appropriately glycosylated HIV-1 envelope as a vaccine antigen.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Czernekova, Lydie $u Department of Immunology, Palacky University in Olomouc, 77100 Olomouc, Czech Republic.
700    1_
$a Moldoveanu, Zina $u Department of Microbiology, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
700    1_
$a Zachova, Katerina $u Department of Immunology, Palacky University in Olomouc, 77100 Olomouc, Czech Republic.
700    1_
$a Elliott, Matt C $u Department of Microbiology, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
700    1_
$a Novak, Zdenek $u Department of Surgery, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
700    1_
$a Hall, Stacy $u Department of Microbiology, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
700    1_
$a Hoelscher, Michael $u Department of Infectious Diseases & Tropical Medicine, Clinic of the University of Munich, Munich, Germany.
700    1_
$a Maboko, Leonard $u NIMR-Mbeya Medical Research Programme, Mbeya, Tanzania.
700    1_
$a Brown, Rhubell $u Department of Microbiology, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
700    1_
$a Smith, Phillip D $u Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA ; VA Medical Center, Birmingham, AL 35205, USA.
700    1_
$a Mestecky, Jiri $u Department of Microbiology, University of Alabama at Birmingham, Birmingham, AL 35294, USA ; Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA ; Institute of Microbiology and Immunology, First Faculty of Medicine, Charles University, 12108 Prague, Czech Republic.
700    1_
$a Novak, Jan $u Department of Microbiology, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
773    0_
$w MED00163149 $t AIDS research and therapy $x 1742-6405 $g Roč. 11, č. - (2014), s. 23
856    41
$u https://pubmed.ncbi.nlm.nih.gov/25120578 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20141006 $b ABA008
991    __
$a 20210121125412 $b ABA008
999    __
$a ind $b bmc $g 1042718 $s 873747
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2014 $b 11 $c - $d 23 $i 1742-6405 $m AIDS research and therapy $n AIDS Res Ther $x MED00163149
LZP    __
$a Pubmed-20141006

Find record

Citation metrics

Archiving options